GnRH super-agonist delivered as a biodegradable subcutaneous depot.
Reference facts
- Also known as
- Zoladex
- Category
- GnRH & Reproductive
- Mechanism of action
- GnRH super-agonist delivered as a biodegradable subcutaneous depot.
- Targets
- GnRH receptor
- Indications under research or approved
- Prostate cancer, Breast cancer (premenopausal, ER+), Endometriosis
- Regulatory status (reference entry)
- FDA-approved (1989)
- Half-life
- ~4 hours (subcutaneous depot)
- Sequence notes
- Decapeptide pyroGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-AzaGly-NH2.
- Molecular weight (Da)
- 1269
- Originator / sponsor
- AstraZeneca
- First reported
- 1976
Primary References
Explore research articles about Goserelin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.